NCT01242826View on ClinicalTrials.gov

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

DiabetesHealthy

Interventions

DRUG

biphasic insulin aspart 50

A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection

Trial Locations (1)

100730

Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY